Pemvidutide^↗

"pemvidutide"[Title/Abstract] OR "alt 801"[Title/Abstract] OR "alt 801"[Title/Abstract]

• Registry comparison, additional aliases and references, and regulator reconciliation require separate checks.
• Original phase 2 MASLD report PMID39002641 has a publisher correction whose full content remains unavailable; the corrected report is not summarized here.
• The 24-week report identifies an extension of the earlier 12-week study; its NCT05292911 extension is grouped with parent NCT05006885. The three included reports still require full-text appraisal and correction reconciliation.
• The modeling supplement cites a 2022 first-in-human presentation; that original presentation and its study-family relationship remain unappraised. Excluding this secondary analysis does not discard the citation lead.

Showing 16 of 16 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

1. PubMed 41237796 — include: Primary human trial or extension report; the selected abstract establishes the trial identity, while full-text appraisal and registry history remain separate. Study families: NCT05989711.
2. PubMed 41113119 — include: Primary human trial or extension report; the selected abstract establishes the trial identity, while full-text appraisal and registry history remain separate. The 24-week report follows completers of the original 12-week MASLD study; NCT05292911 is its extension registry. The parent and extension are retained as one study family. Study families: NCT05006885.
3. PubMed 39002641 — include: Primary human trial or extension report; the selected abstract establishes the trial identity, while full-text appraisal and registry history remain separate. Study families: NCT05006885.
4. PubMed 42529769 — exclude: Secondary review, commentary or research overview; not a primary human-administration report for this molecule.
5. PubMed 41879841 — exclude: Secondary review, commentary or research overview; not a primary human-administration report for this molecule.
6. PubMed 41696398 — exclude: Secondary review, commentary or research overview; not a primary human-administration report for this molecule.
7. PubMed 41661442 — exclude: Cross-species pharmacokinetic modeling reuses pemvidutide human data from a 2022 first-in-human presentation (supplement Table S1, page 5; reference 11, page 12). It is not an additional primary human-administration report. The presentation remains a citation lead, not a newly appraised trial.
   Full-text eligibility check · PMC13038672

   Read the source full text ↗ · sections Methods: The Dataset of Peptide Drug Pharmacokinetics, Data availability.

   Source supplementary files ↗

   • 40262_2025_1615_MOESM1_ESM.pdf · Table S1: pemvidutide human row (page 5), Reference 11 (page 12) · SHA-256 2b22d67fac8dd7e88b4cad561180e5f83ea9c83609b04ac584e6e163f0aad985.

   This reading establishes eligibility for this search; it is not a full appraisal of the study.

   Reviewed 2026-09-15; source SHA-256 c4ded6a9a4a4a2c98a1e749a9a47f519b6f7c4470675544bbfe80d5168947262.

8. PubMed 41352959 — exclude: The author disclosure in the PubMed record explicitly identifies this article as a Comment. It discusses the phase 2b trial rather than reporting an additional primary human-administration study.

   Eligibility source ↗ · Conflict-of-interest statement: author identifies this as a Comment · read 2026-09-15.

9. PubMed 41362110 — exclude: Secondary review, commentary or research overview; not a primary human-administration report for this molecule.
10. PubMed 40734920 — exclude: Secondary review, commentary or research overview; not a primary human-administration report for this molecule.
11. PubMed 40081498 — exclude: Secondary review, commentary or research overview; not a primary human-administration report for this molecule.
12. PubMed 40063921 — exclude: Secondary review, commentary or research overview; not a primary human-administration report for this molecule.
13. PubMed 39676791 — exclude: Secondary review, commentary or research overview; not a primary human-administration report for this molecule.
14. PubMed 35461369 — exclude: Preclinical, genetic or mechanistic study; no primary administration of this molecule to people is reported in the inspected abstract.
15. PubMed 21994418 — exclude: ALT-801 here refers to an oncology IL-2/T-cell-receptor fusion program or a multi-drug trial roundup, not the pemvidutide GLP-1/glucagon agonist.
16. PubMed 20383346 — exclude: Multi-drug clinical-trial roundup; does not supply a primary report of pemvidutide administration.

products.active_ingredients.name:"PEMVIDUTIDE"

• Zero results describe this query response only, not absence of FDA approval or worldwide nonapproval.
• This endpoint does not inventory every label, advisory proceeding, safety communication or regulatory document. Application inclusion does not establish current marketing or approval of every use.

Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

Case-insensitive word-boundary identity terms: ["Pemvidutide", "ALT-801"]

• Document appraisal and national European sources remain open.
• Zero matches apply only to these feed fields and terms; orphan designation is not approval.

Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

Case-insensitive word-boundary identity terms: ["Pemvidutide", "ALT-801"]

• Document appraisal and national European sources remain open.
• Zero matches apply only to these feed fields and terms; orphan designation is not approval.

Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

Case-insensitive word-boundary identity terms: ["Pemvidutide", "ALT-801"]

• Document appraisal and national European sources remain open.
• Zero matches apply only to these feed fields and terms; orphan designation is not approval.

Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

"Pemvidutide" OR "ALT-801"

• Registration is not evidence that a study succeeded, that results were published, or that a use is approved.
• Other registries, unregistered studies and additional aliases remain outside this query.

Showing 16 of 16 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

1. ClinicalTrials.gov NCT07009860 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
2. ClinicalTrials.gov NCT01670994 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
3. ClinicalTrials.gov NCT01326871 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
4. ClinicalTrials.gov NCT05295875 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
5. ClinicalTrials.gov NCT06987513 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
6. ClinicalTrials.gov NCT00496860 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
7. ClinicalTrials.gov NCT05292911 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
8. ClinicalTrials.gov NCT01029873 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
9. ClinicalTrials.gov NCT01478074 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
10. ClinicalTrials.gov NCT04972396 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
11. ClinicalTrials.gov NCT04561245 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
12. ClinicalTrials.gov NCT05134662 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
13. ClinicalTrials.gov NCT01625260 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
14. ClinicalTrials.gov NCT07795164 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
15. ClinicalTrials.gov NCT05006885 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
16. ClinicalTrials.gov NCT05989711 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.